Nov 5, 2010 – Cymbalta (duloxetine), first approved as an anti-depressant in 2004 and as a drug for symptoms of fibromyalgia in 2008, has now been approved for the more general treatment of “chronic musculoskeletal pain, stemming form conditions including lower back pain and osteo arthritis,” according to a news release from the US Department of Health & Human Services.
According to the release:
“Since its approval as an antidepressant in 2004, some 30 million people in the United States have used the drug, the agency [FDA] said in a news release. The FDA also has sanctioned Cymbalta for diabetic pain, generalized anxiety disorder and fibromyalgia.
“The most common side effects from Cymbalta use include nausea, dry mouth, insomnia, drowsiness, constipation, fatigue, and dizziness. More serious adverse reactions have included liver damage, allergic reaction, pneumonia, depressed mood, and suicidal thoughts and behavior, the agency said.
“Cymbalta is produced by Eli Lilly and Co., based in Indianapolis."